The AI cloud company is marketing convertible senior notes due 2033, with expected pricing that could bring the total offering to as much as $3.5 billion.

The Class B term loan is intended to support origination growth and platform expansion at the Morristown, New Jersey equipment-finance company.

North Immunology investors are expected to own about 95.25% of the combined company, with the financing intended to fund development of bispecific antibody candidate NOR-101 into 2028.

The Marea acquisition closed September 17, while Lisata’s $225 million private placement is expected to close September 18 and fund the combined business into 2028.

The merged insurer said close to half of its CHF 650 million annual run-rate savings target was already secured by June, prompting a higher year-end target while merger integration costs remain within guidance.

Proceeds are set to retire most 2028 notes and all 2030 notes, while Grünenthal’s €675 million 2031 secured notes stay outstanding.

Brookfield will pay US$3.38 in cash for each RWC share under a binding scheme, with the Australian-dollar equivalent around A$4.75 at the September 15 exchange rate.

Santersus holders are expected to own about 85% of the combined company, which plans to adopt the Santersus Bio name and SNTS ticker after closing.

Apollo and KKR have invested equity in an entity holding Bayer’s long-acting reversible contraceptives business, while Bayer keeps a majority stake and full operational control.

The French hearing-loss biotech is evaluating a U.S. offering of ordinary shares, including American Depositary Shares, but has not announced the size, price range, exchange or timetable.